Other Event

Other Event

Other Adverse Events are non-serious adverse events that exceed a specific frequency threshold (typically 5% within any study arm). These events are reported to provide comprehensive safety information about all noteworthy adverse occurrences during clinical trials. Each other event is categorized by term, organ system, assessment type, and source vocabulary for standardized reporting.

Other Event path is as follows:

Study -> Results Section -> Adverse Events Module -> Other Event

Study -> Results Section -> Adverse Events Module -> Other Event -> Other Event Stats

Other Event


Ignite Creation Date: 2025-12-24 @ 7:51 PM
Ignite Modification Date: 2025-12-25 @ 5:27 PM
NCT ID: NCT02960204
Term: Hepatocellular carcinoma
Organ System: Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Assessment Type: SYSTEMATIC_ASSESSMENT
Source Vocabulary: MedDRA (18.1)
Notes: Hepatocellular carcinoma, Hepatic neoplasm, Breast cancer, colon cancer, prostate cancer, renal cancer, squamous cell carcinoma.
Study: NCT02960204
Study Brief: Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
Other Event Stats (If Any):

Other Event Stats

Group ID # Events # Affected # At Risk View
EG000 4 4 65 View
EG001 6 6 65 View
EG002 3 3 66 View
EG003 4 4 67 View